Belite Bio
Market cap $6.35B 40.3M shares (vendor count, Nov 18, 2026) × $157.72 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-31
- tinlarebant PDUFA dateFeb 12, 2027tinlarebant PDUFA date, Feb 12, 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
LBS-009
Capital (as filed)
- Cash
- $353M cash and cash equivalents · Dec 31, 2025 (20-F)
- Operating cash flow
- −$9.2M annual ÷ 4, year to Dec 31, 2025 (20-F)
- As stated in coverage
- $774M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
- 2026-11-13 UPDATE: Belite Bio (BLTE) - No Committee, No Public Trial 🔒 Paid
- 2026-09-09 UPDATE: Belite Bio (BLTE) - A Second Flag on the Board 🔒 Paid
- 2026-08-12 UPDATE: Belite Bio (BLTE) - The Clock Is Set 🔒 Paid
- 2026-07-22 Belite Bio (BLTE) — Scientific Deep Dive for Tinlarebant (LBS-008) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Belite Bio, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-07-22 Watch Belite Bio (BLTE) — Scientific Deep Dive for Tinlarebant (LBS-008) and Pipeline Products Stargardt science is genuinely de-risked and balance sheet is a fortress, but at ~$6B near all-time highs the stock already prices in approval plus GA success while the vision-benefit and PHOENIX questions remain open.
- 2026-08-12 Speculative buy speculative UPDATE: Belite Bio (BLTE) - The Clock Is Set FDA accepted the single-pivotal NDA with Priority Review and a February 12, 2027 PDUFA — the precise named de-risking event that triggers an upgrade — though the vision-benefit and PHOENIX questions remain open, warranting only a partial position.
- 2026-09-09 Speculative buy speculative UPDATE: Belite Bio (BLTE) - A Second Flag on the Board Japan NDA filed under Sakigake widens the STGD1 base case incrementally, but the upgrade trigger for a full BUY — DRAGON II confirmation or positive PHOENIX interim — remains unmet, keeping the stance at speculative with tranche discipline.
- 2026-11-13 Speculative buy speculative UPDATE: Belite Bio (BLTE) - No Committee, No Public Trial FDA skipping an advisory committee removes the most visible pre-PDUFA risk for a single-pivotal imaging-endpoint filing, and the stock is ~12% off its highs, making gradual accumulation on weakness more defensible, though the full-BUY trigger of DRAGON II or PHOENIX remains unmet.
- Long call · opened Aug 12, 2026 at $178.94 · -11.9% vs XBI -8.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The FDA has set a Prescription Drug User Fee Act (PDUFA) date of February 12, 2027.”
matched to tinlarebant (STGD1) · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026424B5Prospectus supplement (offering)
- Nov 12, 2026ReleaseBelite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update→ BD updateSummary on the 6-K
- Nov 12, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateThe FDA has confirmed it will not convene an advisory committee for tinlarebant's STGD1 NDA — the single most telling signal that the agency isn't escalating the functional-benefit debate, removing a tail risk I'd flagged explicitly and clearing the regulatory runway to the February 12, 2027 PDUFA date.
- Nov 5, 2026ReleaseBelite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
- Oct 19, 2026ReleaseBelite Bio Announces Uplisting to the Nasdaq Global Select Market
- Oct 19, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Oct 14, 2026ReleaseBelite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
- Sep 8, 2026ReleaseBelite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Dis→ BD updateSummary on the 6-KBD extracted 1 program update from this document → BLTE pipeline
- Sep 8, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateBelite Bio filed a Japan NDA for tinlarebant under Sakigake designation — the same expedited pathway that could make it the first-ever ophthalmology drug approved under Sakigake — adding a second regulatory clock to the February 2027 FDA PDUFA and a 9,500-patient Japan market to the commercial case.
- Sep 1, 2026ReleaseBelite Bio to Participate in Four Upcoming Investor Conferences
- Aug 24, 2026ReleaseBelite Bio to Host Virtual Commercial Day on September 2, 2026
- Aug 21, 2026ReleaseBelite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesBD extracted 1 program update from this document → BLTE pipeline
- Aug 13, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Aug 12, 2026ReleaseBelite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate UpdateBD extracted 1 program update from this document → BLTE pipeline
- Aug 11, 2026ReleaseBelite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1BD extracted 1 program update from this document → BLTE pipeline
- Aug 11, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Aug 6, 2026ReleaseBelite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
- Jun 15, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 20, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Apr 21, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 31, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 31, 202620-FAnnual report (foreign)
- Mar 2, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)
- May 14, 2026SCHEDULE 13G/A13G amendment